Chiesa, S. T., Charakida, M., Georgiopoulos, G., Roberts, J. D., Stafford, S. J., Park, C., Mykkänen, J., Kähönen, M., Lehtimäki, T., Ala‐Korpela, M., Raitakari, O., Pietiäinen, M., Pussinen, P., Muthurangu, V., Hughes, A. D., Sattar, N., Timpson, N. J., & Deanfield, J. E. (2022). Glycoprotein acetyls: A novel inflammatory biomarker of early cardiovascular risk in the young. Journal of the American Heart Association, 11(4), e024380. https://doi.org/10.1161/JAHA.121.024380
Glycoprotein acetyls : a novel inflammatory biomarker of early cardiovascular risk in the young
|Author:||Chiesa, Scott T.1; Charakida, Marietta2; Georgiopoulos, Georgios2;|
1Institute of Cardiovascular Science, University College London, UK
2Department of Imaging Science and Biomedical Engineering, King’s College London, UK
3Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
4Molecular Diagnostics Unit, Medical Technology Research Centre, Faculty of Health, Education, Medicine & Social Care, Anglia Ruskin University, Chelmsford, UK
5Cardiometabolic Phenotyping Group, Institute of Cardiovascular Science, University College London, UK
6Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Finland
7Centre for Population Health Research, University of Turku and Turku University Hospital, Finland
8Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland
9Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
10Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland
11Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Finland
12Center for Life Course Health Research, University of Oulu, Finland
13NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
14Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
15Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
16Centre for Cardiovascular Imaging, UCL Institute of Cardiovascular Science, London, United Kingdom
17MRC Unit for Lifelong Health and Ageing, University College London, UK
18Institute of Cardiovascular and Medical Sciences, British Heart Foundation (BHF) Glasgow Cardiovascular Research Centre, University of Glasgow, UK
19Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, UK
20Medical Research Council Integrative Epidemiology Unit, University of Bristol, UK
|Online Access:||PDF Full Text (PDF, 1.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022081855778
John Wiley & Sons,
|Publish Date:|| 2022-08-18
Background: Low‐grade inflammation in the young may contribute to the early development of cardiovascular disease. We assessed whether circulating levels of glycoprotein acetyls (GlycA) were better able to predict the development of adverse cardiovascular disease risk profiles compared with the more commonly used biomarker high‐sensitivity CRP (C‐reactive protein).
Methods: A total of 3306 adolescents and young adults from the Avon Longitudinal Study of Parents and Children (mean age, 15.4±0.3; n=1750) and Cardiovascular Risk in Young Finns Study (mean age, 32.1±5.0; n=1556) were included. Baseline associations between inflammatory biomarkers, body composition, cardiovascular risk factors, and subclinical measures of vascular dysfunction were assessed cross‐sectionally in both cohorts. Prospective risk of developing hypertension and metabolic syndrome during 9‐to‐10‐year follow‐up were also assessed as surrogate markers for future cardiovascular risk. GlycA showed greater within‐subject correlation over 9‐to‐10‐year follow‐up in both cohorts compared with CRP, particularly in the younger adolescent group (r=0.36 versus 0.07). In multivariable analyses, GlycA was found to associate with multiple lifestyle‐related cardiovascular disease risk factors, cardiometabolic risk factor burden, and vascular dysfunction (eg, mean difference in flow‐mediated dilation=−1.2 [−1.8, −0.7]% per z‐score increase). In contrast, CRP levels appeared predominantly driven by body mass index and showed little relationship to any measured cardiovascular risk factors or phenotypes. In both cohorts, only GlycA predicted future risk of both hypertension (risk ratio [RR], ≈1.1 per z‐score increase for both cohorts) and metabolic syndrome (RR, ≈1.2–1.3 per z‐score increase for both cohorts) in 9‐to‐10‐year follow‐up.
Conclusions: Low‐grade inflammation captured by the novel biomarker GlycA is associated with adverse cardiovascular risk profiles from as early as adolescence and predicts future risk of hypertension and metabolic syndrome in up to 10‐year follow‐up. GlycA is a stable inflammatory biomarker which may capture distinct sources of inflammation in the young and may provide a more sensitive measure than CRP for detecting early cardiovascular risk.
Journal of the American Heart Association
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and STC will serve as guarantor for the contents of this paper. This research was specifically funded through grants from the British Heart Foundation (PG/18/45/33814; CS/15/6/31468), Wellcome Trust and MRC (076467/Z/05/Z), and NIH (R01 DK077659). The Young Finns Study has been financially supported by the Academy of Finland: grants 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation and the Finnish Society of Clinical Chemistry. MAK has a research grant from the Sigrid Juselius Foundation, Finland.
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.